Chairpersons :

R. Gopal, Manohar Chari, N. Sudhakar

Reviewer :

Jaya Ghosh

1. Increasing the dose density of adjuvant chemotherapy by shortening intervals

between courses or by sequential drug administration significantly reduces both

disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000

women in 16 randomised trials

Author: Gray R.

Citation: SABCS ABSTRACT GS1-01

2. NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant

chemotherapy with Adriamycin (A) and Cyclophosphamide (C) ® Weekly Paclitaxel

(WP), or Docetaxel (T) and C with or without a year of Trastuzumab (H) in women with

node-positive or high-risk node-negative Invasive Breast Cancer (IBC) expressing HER2

staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

Author: Fehrenbacher L.

Citation: SABCS ABSTRACT GS1-02

3.Prospective WSG phase III plan B trial: Final analysis of adjuvant 4xEC®4x doc vs. 6x

docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-tohigh

genomic risk HER2-negative, early breast cancer

Author: Nadia Harbeck

Citation: ASCO Abstract 504 Journal of Clinical Oncology 35, no. 15_suppl (May 2017)

504-504